ArticleNature communications2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Abstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Review
- CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.Cell death & disease · 2026Article
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration.iScience · 2025Article
- A Patient-Derived Organoid Platform from TUR-P Samples Enables Precision Drug Screening in Advanced Prostate Cancer.Cancers · 2025Article
- Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology.Molecular oncology · 2025Article
- Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.European urology focus · 2025Article
- Review
- New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.Research (Washington, D.C.) · 2025Review
- Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.Cancer research · 2024Article
- CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.British journal of cancer · 2024Article
- Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel, Switzerland) · 2024Review
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends in cancer · 2024Review
- FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.Nature communications · 2024Article
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.Molecular cancer research : MCR · 2024Article
- Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.BMC cancer · 2024Article
Corrections and comments
- Commented on by
Authors and funding
45 authors.
Gail P Risbridger *Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia. gail.risbridger@monash.edu.ORCID 0000-0003-3089-4028
Ashlee K Clark *Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Laura H Porter *Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Roxanne ToivanenProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Andrew BakshiProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Natalie L ListerProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
David PookProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Carmel J PezaroProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Shahneen SandhuSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Shivakumar KeerthikumarCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rosalia Quezada UrbanCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Melissa PapargirisProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Jenna KraskaProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Heather B MadsenProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Hong WangProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Michelle G RichardsProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Birunthi NiranjanProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Samantha O'DeaProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Linda TengProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
William JenkinsProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Zhuoer LiProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Physiology, Monash University, Clayton, VIC, Australia.
Nicholas ChooProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
John F OuyangProgram in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore.ORCID 0000-0002-1239-1577
Heather ThorneCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Lisa DevereuxCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0003-2435-5888
Rodney J HicksCenter for Molecular Imaging, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.ORCID 0000-0002-0758-0824
Shomik SenguptaEastern Health and Monash University Eastern Health Clinical School, Box Hill, VIC, Australia.
Laurence HarewoodEpworth Healthcare, Melbourne, VIC, Australia.
Mahesh IddawalaProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Arun A AzadSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0001-7350-5622
Jeremy GoadSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Jeremy GrummetEpworth Healthcare, Melbourne, VIC, Australia.
John KourambasDepartment of Medicine, Monash Health, Casey Hospital, Berwick, VIC, Australia.
Edmond M KwanDepartment of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-7053-680X
Daniel MoonEpworth Healthcare, Melbourne, VIC, Australia.
Declan G MurphySir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0002-7500-5899
John PedersenProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
David CloustonTissuPath, Mount Waverley, VIC, Australia.
Sam NordenTissuPath, Mount Waverley, VIC, Australia.
Andrew RyanTissuPath, Mount Waverley, VIC, Australia.
Luc FuricProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-1893-9812
David L GoodeCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Mark FrydenbergProstate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
Mitchell G Lawrence *Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.ORCID 0000-0001-9520-3000
Renea A Taylor *Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. renea.taylor@monash.edu.ORCID 0000-0003-2609-2380
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer.
Indexed as
AnimalsDisease Models, AnimalDrug Evaluation, PreclinicalGenomeHumansMaleMiceMice, Inbred NODMice, SCIDMutationNeoplasm MetastasisOrganoidsProspective StudiesProstatic NeoplasmsTissue BanksTranscriptome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.